Using same PCa cohort data, we found that, while SHBG expression was downregulated in patients with CRPC compared with their peers in the tumor or benign group, howbeit statistically insignificant (t = 0.40, p = 0.67), relative to the benign group, SRD5A1 expression was significantly upregulated in the tumor and CRPC groups (t = 11.39, p = 0.000021) (Figure 7B). Here, SRD5A1 is linked to posterior cortical atrophy.